The TD Symptoms Patients Stop Mentioning

A patient on the same antipsychotic for six years comes in for a routine medication-management appointment. The visit runs twenty minutes, and most of it is spent on her chief complaint: sleep, energy, a new stressor at work. The regimen is stable, her mood is stable, and the chart is unremarkable. She does not mention the way her tongue has begun moving when she is concentrating, because she has not noticed it in months. Her family stopped commenting on it years ago. Her clinician notices nothing during the visit because the movements are subtle and intermittent, and the encounter does not include a focused movement assessment. The appointment ends. The next one is in three months.

This is the pattern that Tardive Dyskinesia Awareness Month, observed each May, is trying to interrupt. The first full week of May is TD Awareness Week, and the awareness conversation has done what awareness conversations do. It has named the problem clearly. An estimated 800,000 U.S. adults are living with TD, and roughly 60% remain undiagnosed. The harder question, and the one the field has not solved, is what happens in the room when the appointment is twenty minutes and nobody brings the symptom up.

Why the symptom goes unspoken

Tardive dyskinesia rarely announces itself. The movements develop gradually, sometimes over months and years, and patients adapt to them on a timeline that mirrors their development. Lip pursing, tongue movements, finger fidgets, brief facial movements: these become part of the familiar self before they ever feel like something to report. Many patients attribute the changes to aging, to anxiety, to caffeine, or to “always doing that.” Some have been told, directly or by implication, that the medication is keeping them stable and that questioning it is risky. Some are simply embarrassed to describe a movement they cannot consistently control.

This is not unreliability. It is adaptation, and adaptation is one of the things human nervous systems do best. The clinical implication is that the standard input for catching TD, the patient’s spontaneous report, is the input most likely to fail. By the time a patient describes a movement clearly enough to act on, the movements have often been present for some time.

The standard backup, the clinician’s observation during a brief visit, has its own well-known limits. The Abnormal Involuntary Movement Scale (AIMS) is the field’s reference tool, and it is reliable when administered well. It also takes time to administer well, and adult medication-management visits often run shorter than that for the entire encounter. Movements can be intermittent, attenuated by the patient’s attention to them, and easier to see during specific maneuvers that a focused exam includes and a routine visit often does not. The American Psychiatric Association’s 2020 schizophrenia practice guideline recommends a structured TD assessment at least every six months for patients at higher risk and at least every twelve months for others on long-term antipsychotic therapy, with brief inquiry at every encounter. In real-world adult outpatient practice, the structured cadence is uneven.

None of this is a failure of clinician attention. It is a workflow shaped by a particular kind of visit, a particular set of time constraints, and a symptom that does not always cooperate with that format.

What changes when a screen opens the conversation

A different shape of conversation becomes possible when a structured movement assessment is part of the encounter rather than dependent on it. TDScreen, the free, video-based AI screening tool from Videra Health, was built for that purpose. Providers and healthcare organizations integrate it into their workflow, and patients complete a five-minute video screening on a phone, in the office or at home. The result becomes a starting point for the next clinical conversation. The screen does not diagnose, and it does not prescribe. It surfaces a pattern that may or may not warrant a closer look, and it gives the patient and the clinician something specific to talk about.

New real-world data published April 2026 describes what that has looked like since TDScreen launched in May 2024. More than 9,400 screenings have been completed across 8,600 unique patients, with 757 providers and healthcare organizations using the tool. Among the more than 2,000 patients who responded to follow-up outreach, 548 reported discussing their results with a clinician. 156 received a TD diagnosis. 125, or 80% of those diagnosed, were prescribed treatment.

The number that does the most work in this story is the 548. That is the count of conversations prompted by something other than the patient deciding, on their own, to bring up a movement they may have stopped noticing. Diagnosis still belongs to the clinician. The press release notes plainly that TDScreen is designed to support clinical decision-making, not replace evaluation by a qualified provider. The screen is the thing that opened the door.

One patient quoted in the announcement put the case more simply than any data point can: “If it wasn’t for this screening, I wouldn’t have mentioned my symptoms to my provider. My quality of life is so much better now that I am managing them.”

What this changes about the visit

The 80% number is meaningful, and it deserves context. A TD diagnosis does not always lead to immediate medication treatment. Mild presentations are sometimes monitored over time, with the conversation revisited at the next visit. The data from this cohort reflects a meaningful share of patients who, with their clinicians, decided that pursuing treatment was the right next step. Other patients in the cohort may have moved to a closer monitoring plan, a regimen adjustment, or a referral. Each of those is also a clinical outcome that depends on the conversation having happened.

The visit that includes a screen looks different in another way. The patient comes in with information about their own movements. The clinician receives a structured starting point that does not depend on chief-complaint time being short. The patient who would have left without mentioning the symptom now has a reason to ask, “what does this mean?” The conversation moves from a question the patient might never raise to a question the patient and clinician are answering together. This is the same pattern Videra has explored in other forms of objective behavioral health measurement: structured signal does not replace the clinical relationship, it gives the relationship more honest material to work with.

Looking ahead

What TD Awareness Month asks of the field this year is not more posters in the waiting room. It is a workflow that produces the conversation. The pattern of underdiagnosis has been documented, written about, and lamented for years. The pattern of patient adaptation, which sits underneath the underdiagnosis pattern, is less often named. Naming it has implications for how the field designs the visit. Self-report cannot be the only sensor for a symptom that adaptation hides. A structured, low-friction screen, used as a conversation-starter rather than as a verdict, gives both the patient and the clinician a more honest place to begin.

The screening tool is free. The conversation it opens is the part that matters. TD Awareness Month gets the headlines. The conversation is what changes the chart.

---

TDScreen is free for any provider or healthcare organization that wants to add structured TD screening to their workflow, and free for any patient who wants to complete one. Providers can create an account in a few minutes at TDScreen.ai. For a closer look at the AI methodology behind movement-disorder screening, see Videra Health’s Building Disease-Specific Predictive Algorithms case study.